pacritinib
Trade name: Vonjo
Small moleculeapprovedOrphan Drug FDAFast Track FDA
Approved
Nov 29, 2021
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3). — Wikipedia
Clinical trial activity
64 trials · 52 clinical orgs · 2 marketing orgs
Phase 1
35
Phase 2
38
Phase 3
6
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00741871)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
- Mar 13, 2008
Orphan Drug Designation
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2012
CTI BioPharma — Earliest Phase 3 Sponsor(trial)
2020s
- Nov 29, 2021
On Target Laboratories, LLC — Earliest FDA Approval
- Nov 29, 2021
On Target Laboratories, LLC — Marketing Organization
- Nov 29, 2021
On Target Laboratories, LLC — NDA Secondary Org
- Nov 29, 2021
On Target Laboratories, LLC — NDA Organization
- Feb 28, 2022
CTI BioPharma — Marketing Organization
- Feb 28, 2022
CTI BioPharma — NDA Secondary Org
Indications
Approved for
Studied for
- Arthritis, Rheumatoid · Phase 1
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- COVID-19 · Phase 3
- Drug Interactions · Phase 1
- Drug Therapy · Phase 1
- Graft vs Host Disease · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Hematologic Diseases · Phase 2
- Herpesvirus 8, Human · Phase 2
- Hodgkin Disease · Phase 2
- Inflammatory Bowel Diseases · Phase 1
- Leukemia · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Leukemia, Myelomonocytic, Juvenile · Phase 1
- Liver Diseases · Phase 1
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, T-Cell, Cutaneous · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Lymphoproliferative Disorders · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 2
- Neoplasm Metastasis · Phase 3
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 3
- Pituitary Neoplasms · Phase 1
- Polycythemia Vera · Phase 3
- Primary Myelofibrosis · Phase 3
- Prostatic Neoplasms · Phase 2
- Sarcoma, Kaposi · Phase 2
- Thrombocythemia, Essential · Phase 1/Phase 2
- Thrombocytopenia · Phase 2
- Thrombocytosis · Phase 1
- Waldenstrom Macroglobulinemia · Phase 2
Mechanism of action
- Unspecified targetOTHER
Diagnostic
Interleukin-1 receptor-associated kinase 1 inhibitor
- Activin receptor type-1INHIBITOR
Activin receptor type-1 inhibitor
FLT3 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
Approval history
- approvedPriority reviewAcceleratedFast trackNov 29, 2021
Chemistry & pharmacology
Loading structure…
SMILES
C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2- Mol. weight
- 472.59 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPacritinib ↗
- ChEMBLCHEMBL5095049 ↗
- ChEMBLCHEMBL4594383 ↗
- ChEMBLCHEMBL4297412 ↗
- ChEMBLCHEMBL2035187 ↗
Also known as
- 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
- onx-0803
- onx-0803
- otl38
- pacritinib
- pacritinib
- pacritinib
- pacritinib
- pacritinib
- sb1518
- sb1518
- sb1518
- sb1518
- sb 1518
- sb-1518
- sb-1518
- sb-1518
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07226713 | Phase 2 | Mar 1, 2026 | Medical College of Wisconsin |
| NCT07148947 | Phase 2 | Feb 1, 2026 | Swedish Orphan Biovitrum, University of Washington |
| NCT07033598 | Phase 2 | Dec 31, 2025 | Swedish Orphan Biovitrum, Theradex, University of South Florida |
| NCT06986174 | Phase 2 | Nov 30, 2025 | Harvard University, Swedish Orphan Biovitrum |
| NCT06675123 | Phase 1 | Nov 1, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06782373 | Phase 2 | May 31, 2025 | PSI CRO, Swedish Orphan Biovitrum |
| NCT06915727 | Phase 3 | Apr 15, 2025 | Mayo Clinic |
| NCT06303193 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2024 | National Cancer Institute (NCI) |
| NCT06538181 | Phase 1 | Oct 31, 2024 | Swedish Orphan Biovitrum, Washington University in St. Louis |
| NCT06516887 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2024 | National Cancer Institute (NCI), University of Texas, San Antonio |
| NCT06414681 | Early Phase 1 (Phase 1) | May 31, 2024 | University of Kansas |
| NCT06218628 | Phase 1 | Apr 5, 2024 | Temple University |
| NCT05980806 | Phase 2 | Mar 31, 2024 | Karyopharm Therapeutics Inc |
| NCT06052618 | Phase 2 | Jan 3, 2024 | National Cancer Institute (NCI) |
| NCT06159491 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2024 | Icahn School of Medicine at Mount Sinai, Swedish Orphan Biovitrum |
| NCT05749432 | Phase 1 | Mar 31, 2023 | Hemay Pharmaceutical PTY. LTD. |
| NCT05657613 | Phase 1 | Dec 31, 2022 | CTI BioPharma, PPD |
| NCT05531786 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT05552183 | Phase 1 | Nov 30, 2022 | CTI BioPharma, PPD |
| NCT04941378 | Phase 1 | Aug 31, 2022 | University of Pennsylvania |
Showing 20 of 64 trials
Page 1 / 4
Organizations
Research & Development (52)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CTI BioPharma | For profit | 23 | 15 | 3 | 2012 |
| University of Pennsylvania | Academic/Hospital | 8 | 5 | 3 | 2015 |
| Covance | For profit | 6 | 0 | 2 | 2014 |
| National Cancer Institute (NCI) | Government | 6 | 3 | 2 | 2014 |
| Swedish Orphan Biovitrum | For profit | 6 | 1 | 2 | 2024 |
| University of Texas at Houston | Academic/Hospital | 6 | 3 | 2 | 2008 |
| On Target Laboratories, LLC | For profit | 5 | 4 | 3 | 2014 |
| S*BIO | For profit | 5 | 4 | 2 | 2008 |
| Washington University in St. Louis | Academic/Hospital | 4 | 4 | 2 | 2015 |
| University of Michigan | Academic/Hospital | 3 | 3 | 2 | 2016 |
| University of South Florida | Academic/Hospital | 3 | 1 | 1 | 2008 |
| University of Washington | Academic/Hospital | 3 | 2 | 1 | 2008 |
| Cornell University | Academic/Hospital | 2 | 1 | 1 | 2010 |
| Harvard University | Academic/Hospital | 2 | 1 | 1 | 2008 |
| Mayo Clinic | Academic/Hospital | 2 | 1 | 2 | 2008 |
| Medical College of Wisconsin | Academic/Hospital | 2 | 2 | 1 | 2021 |
| PPD | For profit | 2 | 0 | 1 | 2022 |
| SGS Life Sciences | For profit | 2 | 0 | 1 | 2014 |
| Synteract, Inc. | For profit | 2 | 0 | 2 | 2014 |
| Apex Bioscience | For profit | 1 | 0 | 1 | 2014 |
52 organizations
Page 1 / 3
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| CTI BioPharma | For profit | MKTG | Feb 28, 2022 |
| CTI BioPharma | For profit | NDA2 | Feb 28, 2022 |
| On Target Laboratories, LLC | For profit | MKTG | Nov 29, 2021 |
| On Target Laboratories, LLC | For profit | NDA2 | Nov 29, 2021 |
| On Target Laboratories, LLC | For profit | NDA | Nov 29, 2021 |